Home
Resources
Publications
Comparative Effects of Pirbuterol Acetate, Metaproterenol, and Placebo Aerosols on Pulmonary Function and Incidence of Cardiac Ectopy

Comparative Effects of Pirbuterol Acetate, Metaproterenol, and Placebo Aerosols on Pulmonary Function and Incidence of Cardiac Ectopy

S Chodosh, L A Crooks, J Tuck

J Asthma. 1989;26(5):309-15.

PMID: 2484663

Abstract:

This single-center, double-blind, randomized study compared the efficacy and safety of single-dose pirbuterol aerosol (0.2 mg and 0.4 mg) with metaproterenol (1.3 mg) and placebo aerosols. Twenty-four patients with asthma or chronic obstructive pulmonary disease (COPD) completed this crossover design study. Statistically significant improvement over placebo (p less than 0.05 to p less than 0.001) was noted for pirbuterol 0.2 mg and 0.4 mg in FEV1 (forced expiratory volume in 1 second) duration, peak, and area under the curve (AUC) responses, and in maximum midexpiratory flow rate (MMEF) peak and AUC responses. Pirbuterol at both the 0.2 mg and 0.4 mg doses demonstrated statistically significant improvements in pulmonary function tests and clinical assessment over metaproterenol 1.3 mg. Both drugs were well-tolerated and neither drug increased cardiac ectopy, as measured on 5-h Holter monitor tapes.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
AP65652440-A	Pirbuterol acetate		65652-44-0	Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: